DIRECT EFFECT OF CALCITRIOL ON THE REGULATION OF PARATHYROID-HORMONE SECRETION IN A CASE OF PSEUDO-HYPOPARATHYROIDISM (A 24-MONTH FOLLOW-UP-STUDY)

被引：8

作者：

GIRAUD, P ^{[1
]}

AUDRAN, M ^{[1
]}

ROHMER, V ^{[1
]}

JALLET, P ^{[1
]}

BASLE, MF ^{[1
]}

BREGEON, C ^{[1
]}

BIGORGNE, JC ^{[1
]}

机构：

[1] CHU ANGERS,DEPT RHEUMATOL,SERV RHEUMATOL,F-49033 ANGERS 01,FRANCE

来源：

CLINICAL RHEUMATOLOGY | 1995年 / 14卷 / 03期

关键词：

PARATHYROID HORMONE; PSEUDO-HYPOPARATHYROIDISM; CALCITRIOL; OSTEITIS FIBROSA;

D O I：

10.1007/BF02208341

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The diagnosis of pseudohypoparathyroidism with osteitis fibrosa was made in a 51-year-old woman on the basis of hypocalcaemia, elevated plasma PTH (1-84) and blunted cAMP response to hPTH infusion. Radiologically, widespread signs of hyperparathyroidism were observed and quantitative histomorphometry confirmed the increased bone cellular turnover, Treatment with calcitriol (1,25 dihydroxyvitamin D3) induced a dramatic improvement of bone lesions, During treatment PTH (1- 84) normalized with high dosage of calcitriol in spite of low or subnormal levels of serum calcium, and subsequently increased for each reduction of calcitriol dosage despite normal calcium levels. Our observations support a major and direct effect of 1,25 dihydroxyvitamin D3 on the regulation of parathyroid secretion of parathyroids glands.

引用

页码：287 / 291

页数：5

共 24 条

[1]

Drezner M., Neelon F.A., Lebovitz H., Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal, N Engl J Med, 289, pp. 1056-1060, (1973)

[2]

Rodriguez H.J., Villareal H., Klahr S., Slatopolsky E., Pseudohypoparathyroidism type II: restoration of normal responsiveness to parathyroid hormone by calcium administration, J Clin Endocrinol Metab, 39, pp. 693-700, (1974)

[3]

Frame B., Hanson C.A., Frost H.M., Block M., Arnstein A.R., Renal resistance to parathyroid hormone with osteitis fibrosa. “Pseudohypohyperparathyroïdism”, Am J Med, 52, pp. 311-321, (1972)

[4]

Bell N.H., Khairi M.R.A., Johnston C.C., Stern P.H., DeLuca H.F., Hatra A., Meunier P., Edouard C., Alexandre C., Effects of 1,25-dihydroxyvitamin D3 on calcium metabolism and quantitative bone histology in pseudo-hypoparathyroidism, Endocrinology of Calcium Metabolism, pp. 33-38, (1978)

[5]

Drezner M.K., Neelon F.A., Haussler M., Mc. Pher-son H.T., Lebovitz H.E., 1,25-dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism, J Clin Endocrinol Metab, 42, pp. 621-628, (1976)

[6]

Belsey R.E., De Luca H.F., Potts J.A., A rapid assay for 25-OH vitamin D3 without preparative chromatography, J Clin Endocrinol Metab, 38, pp. 1046-1051, (1974)

[7]

Reinhardt T.A., Horst R.L., Orf J.W., Hollis B.W., A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies, J Clin Endocrinol Metab, 58, pp. 91-98, (1984)

[8]

Walton R.J., Bijvoet O.L., Nomogram for derivation of renal threshold phosphate concentration, Lancet, 2, (1975)

[9]

Mallette L.E., Synthetic human parathyroid hormone 1—34 fragment for diagnostic testing, Ann Intern Med, 109, pp. 800-804, (1988)

[10]

Igarashi T., Yamamoto M., Yamada M., Ogata E., Katsuragi S., Application of newly synthesized 1–34 parathyroid hormone for diagnostic tests, Pharmatherapeutica, 3, pp. 79-85, (1982)

← 1 2 3 →